Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 3
2008 2
2009 6
2010 6
2011 5
2012 9
2013 12
2014 8
2015 6
2016 11
2017 9
2018 4
2019 7
2020 10
2021 5
2022 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

89 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial.
Vossler DG, Knake S, O'Brien TJ, Watanabe M, Brock M, Steiniger-Brach B, Williams P, Roebling R; SP0982 co-investigators. Vossler DG, et al. J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1067-1075. doi: 10.1136/jnnp-2020-323524. Epub 2020 Aug 18. J Neurol Neurosurg Psychiatry. 2020. PMID: 32817358 Free PMC article. Clinical Trial.
Median treatment duration with lacosamide/placebo was 143/65 days. Risk of developing a second PGTCS during 24-week treatment was significantly lower with lacosamide than placebo (Kaplan-Meier survival estimates 55.27%/33.37%; HR 0.540, 95% CI 0.377 to 0.774; p<0 …
Median treatment duration with lacosamide/placebo was 143/65 days. Risk of developing a second PGTCS during 24-week treatment was sig …
Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.
Baulac M, Rosenow F, Toledo M, Terada K, Li T, De Backer M, Werhahn KJ, Brock M. Baulac M, et al. Lancet Neurol. 2017 Jan;16(1):43-54. doi: 10.1016/S1474-4422(16)30292-7. Epub 2016 Nov 24. Lancet Neurol. 2017. PMID: 27889312 Clinical Trial.
In the full analysis set, 327 (74%) patients in the lacosamide group and 308 (70%) in the carbamazepine-CR group completed 6 months of treatment without seizures. ...INTERPRETATION: Treatment with lacosamide met the predefined non-inferiority criteria when compared …
In the full analysis set, 327 (74%) patients in the lacosamide group and 308 (70%) in the carbamazepine-CR group completed 6 months o …
Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy.
Ben-Menachem E, Grebe HP, Terada K, Jensen L, Li T, De Backer M, Steiniger-Brach B, Gasalla T, Brock M, Biton V. Ben-Menachem E, et al. Epilepsia. 2019 Dec;60(12):2437-2447. doi: 10.1111/epi.16381. Epub 2019 Nov 21. Epilepsia. 2019. PMID: 31755090 Free PMC article. Clinical Trial.
Incidences of drug-related TEAEs and discontinuations due to TEAEs increased by number of comorbid conditions and were lower in patients on lacosamide. SIGNIFICANCE: Long-term (median ~2 years) lacosamide monotherapy was efficacious and generally well tolerated in a …
Incidences of drug-related TEAEs and discontinuations due to TEAEs increased by number of comorbid conditions and were lower in patients on …
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Marson AG, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton CO, Hughes DA, Williamson PR, Baker G, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE. Marson AG, et al. Health Technol Assess. 2021 Dec;25(75):1-134. doi: 10.3310/hta25750. Health Technol Assess. 2021. PMID: 34931602 Free article. Clinical Trial.
FUTURE WORK: SANAD II data could now be included in an individual participant meta-analysis of similar trials, and future similar trials are required to assess the clinical effectiveness and cost-effectiveness of other new treatments, including lacosamide and perampanel. C …
FUTURE WORK: SANAD II data could now be included in an individual participant meta-analysis of similar trials, and future similar trials are …
Safety and efficacy of adjunctive lacosamide in Chinese and Japanese adults with epilepsy and focal seizures: A long-term, open-label extension of a randomized, controlled trial.
Inoue Y, Liao W, Wang X, Du X, Tennigkeit F, Sasamoto H, Osakabe T, Hoshii N, Yuen N, Hong Z. Inoue Y, et al. Epilepsy Res. 2021 Oct;176:106705. doi: 10.1016/j.eplepsyres.2021.106705. Epub 2021 Jun 29. Epilepsy Res. 2021. PMID: 34246118 Free article. Clinical Trial.
This Phase III, long-term, open-label extension (OLE) trial (EP0009; NCT01832038) was conducted to evaluate the long-term safety, tolerability, and efficacy of adjunctive lacosamide (100-400 mg/day) in Chinese and Japanese people with epilepsy (PWE) (16-70 years) who had c …
This Phase III, long-term, open-label extension (OLE) trial (EP0009; NCT01832038) was conducted to evaluate the long-term safety, tolerabili …
Analyses of seizure responses supportive of a novel trial design to assess efficacy of antiepileptic drugs in infants and young children with epilepsy: Post hoc analyses of pediatric levetiracetam and lacosamide trials.
Johnson ME, McClung C, Bozorg AM. Johnson ME, et al. Epilepsia Open. 2021 Jun;6(2):359-368. doi: 10.1002/epi4.12482. Epub 2021 May 3. Epilepsia Open. 2021. PMID: 34033237 Free PMC article. Clinical Trial.
METHODS: We performed post hoc analyses of two randomized, double-blind, placebo-controlled trials of adjunctive levetiracetam (N159; NCT00615615) and lacosamide (SP0969; NCT01921205) in children and adolescents (4-16 years of age) with focal-onset seizures. ...RESULTS: In …
METHODS: We performed post hoc analyses of two randomized, double-blind, placebo-controlled trials of adjunctive levetiracetam (N159; NCT006 …
Effects of Mexiletine and Lacosamide on Nerve Excitability in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
Ruijs TQ, Koopmans IW, de Kam ML, van Esdonk MJ, Koltzenburg M, Groeneveld GJ, Heuberger JAAC. Ruijs TQ, et al. Clin Pharmacol Ther. 2022 Nov;112(5):1008-1019. doi: 10.1002/cpt.2694. Epub 2022 Jul 19. Clin Pharmacol Ther. 2022. PMID: 35762293 Free PMC article. Clinical Trial.

Strength-duration time constant decreased after lacosamide in motor- (ED -0.0342 ms, 95% CI: -0.0571, -0.0112; P = 0.005) and sensory nerves (ED -0.0778 ms, 95% CI: -0.116, -0.0399; P < 0.001). Mexiletine and lacosamide significantly decrease excitability of moto

Strength-duration time constant decreased after lacosamide in motor- (ED -0.0342 ms, 95% CI: -0.0571, -0.0112; P = 0.005) and sensory …
Lacosamide in patients with epilepsy of cerebrovascular etiology.
Rosenow F, Brandt C, Bozorg A, Dimova S, Steiniger-Brach B, Zhang Y, Ferrò B, Holmes GL, Kälviäinen R. Rosenow F, et al. Acta Neurol Scand. 2020 Jun;141(6):473-482. doi: 10.1111/ane.13230. Epub 2020 Mar 13. Acta Neurol Scand. 2020. PMID: 32068241 Clinical Trial.
OBJECTIVES: To assess tolerability and efficacy of lacosamide in adults with cerebrovascular epilepsy etiology (CVEE). MATERIALS AND METHODS: Exploratory post hoc analyses of a double-blind, initial monotherapy trial of lacosamide vs carbamazepine-controlled release …
OBJECTIVES: To assess tolerability and efficacy of lacosamide in adults with cerebrovascular epilepsy etiology (CVEE). MATERIALS AND …
Lacosamide in pediatric and adult patients: comparison of efficacy and safety.
Verrotti A, Loiacono G, Pizzolorusso A, Parisi P, Bruni O, Luchetti A, Zamponi N, Cappanera S, Grosso S, Kluger G, Janello C, Franzoni E, Elia M, Spalice A, Coppola G, Striano P, Pavone P, Savasta S, Viri M, Romeo A, Aloisi P, Gobbi G, Ferretti A, Cusmai R, Curatolo P. Verrotti A, et al. Seizure. 2013 Apr;22(3):210-6. doi: 10.1016/j.seizure.2012.12.009. Epub 2013 Jan 5. Seizure. 2013. PMID: 23298605 Free article. Clinical Trial.
PURPOSE: This multicenter, prospective study investigates the efficacy and safety of lacosamide adjunctive therapy in pediatric and adult patients with uncontrolled epilepsy. ...The most common adverse events were dyspepsia for group A and dizziness for group B. CONCLUSION …
PURPOSE: This multicenter, prospective study investigates the efficacy and safety of lacosamide adjunctive therapy in pediatric and a …
Effects of lacosamide and carbamazepine on lipids in a randomized trial.
Mintzer S, Dimova S, Zhang Y, Steiniger-Brach B, De Backer M, Chellun D, Roebling R. Mintzer S, et al. Epilepsia. 2020 Dec;61(12):2696-2704. doi: 10.1111/epi.16745. Epub 2020 Nov 17. Epilepsia. 2020. PMID: 33200428 Free PMC article. Clinical Trial.
We evaluated serum lipid profiles in adults with newly diagnosed epilepsy, following randomization to lacosamide (LCM) or carbamazepine (CBZ) monotherapy. METHODS: We analyzed data from a Phase 3, international, randomized, double-blind trial of LCM vs CBZ for the initial …
We evaluated serum lipid profiles in adults with newly diagnosed epilepsy, following randomization to lacosamide (LCM) or carbamazepi …
89 results